2024

Senior Representatives of Curadev attended:

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

• 10th Immunotherapy of Cancer Conference, Munich, Germany where Curadev presented poster titled : Discovery of CRD 1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity and CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability

2023

Senior Representatives of Curadev attended:

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

• The Annual meeting of the American Society for Cancer Research (AACR), San Diego, CA

• The Society for Immunotherapy of Cancer (SITC), San Diego, USA where Curadev presented poster titled: Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity

2022

Senior Representatives of Curadev attended:

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

• The Annual meeting of the American Society for Cancer Research (AACR), New Orleans, Louisiana where Curadev presented poster titled :Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors and  CRD1600 is a potent HPK-I inhibitor with robust immune modulatory properties 

​

2021

Mr. Manish Tandon was invited as a Guest Speaker in the virtual event celebrating World Intellectual Property Week co-organized by FICPI, INTA, AIPPI, APAA, and Lex Witness

​

2020

Senior Representatives of Curadev attended:

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

Senior Representatives of Curadev were invited as speakers:

• Dr. Arjun Surya gave a talk at the Annual Biological Sciences and Bioengineering (BSBE) Symposium in IIT, Kanpur

• Dr. Arjun Surya was invited as a Guest Speaker in the "International Conference on Drug Discovery" organized at BITS Pilani, Hyderabad from 29th February to 2nd March

​

2019

Senior Representatives of Curadev attended:

• The Annual meeting of the European Society for Medical Oncology (ESMO), Barcelona, Spain

• The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

• The Annual meeting of BIO, San Francisco, USA

• The Annual meeting of the American Society for Cancer Research (AACR), Atlanta, USA. Curadev presented poster titled: CRD5500: A versatile small molecule STING agonist amenable to bioconjugation as an ADC

• The Mastering Medicinal Chemistry Conference, Boston, USA

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

2018

Senior Representatives of Curadev attended:

• The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

• BIO-Europe, Copenhagen, Denmark

• The Annual BIO meeting, Boston, USA

• The Annual meeting of the European Society for Medical Oncology (ESMO), Barcelona, Spain

• The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

• The Annual meeting of the American Society for Cancer Research (AACR), Chicago, USA. Curadev presented poster titled: Small molecule ACSS2 inhibitors target acetate metabolizing tumor cells in hypoxic conditions

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

• Researcher Summit organized by DBT and CRUK

​

2017

Senior Representatives of Curadev attended:

• The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

• The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore

• The Annual BIO meeting, San Diego, USA

• The Tumor Immunology and Immunotherapy meeting of the in Boston, USA

• The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

• The Annual meeting of the American Society for Cancer Research (AACR), Washington,DC, USA. Curadev presented poster titled: Novel small-molecule human STING agonists generate robust Type I interferon responses in tumors

• The Annual J.P. Morgan Health Care Conference, San Francisco, USA

• The Keystone Symposium on Tumor Metabolism and Hypoxia, Whistler, Canada

​

2016

Senior Representatives of Curadev attended:

• The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

• The Annual meeting of the American Society for Cancer Research (AACR), New Orleans, USA where Curadev and Roche scientists presented a jointly authored poster titled: RG70099: A novel, highly potent dual TDO/IDO1 inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment.

• The Mastering Medicinal Chemistry Conference, Boston, USA

• The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

• The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore

• The Annual BIO meeting, San Francisco, USA

​

2015

Senior Representatives of Curadev attended:

• A special event at the invitation of the Department of Biotechnology to join an elite delegation headed by the Prime Minister of India, to participate in Indo US Startup Konnect Silicon Valley, USA

• The Annual BIO meeting, Philadelphia, USA

• The Immunotherapy of Cancer (ITOC) conference in Munich, Germany

​

2014

Senior Representatives of Curadev attended:

• The Tumor Immunology and Immunotherapy meeting of the American Society for Cancer Research (AACR) in Orlando, USA where Curadev presented a poster titled: a small molecule dual inhibitor of TDO and IDO

• The Annual BIO meeting, San Diego, USA

• The Annual BIO Asia International Conference meeting, Tokyo, Japan

• The Immunotherapy of Cancer (ITOC) conference in Munich, Germany

​

2013

Senior Representatives of Curadev attended:

•  The Annual BIO meeting, Chicago, USA

​